Compare Boeing Co (BA) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs Biogen Inc — how do they compare? Boeing Co trades at $231.74 (market cap $184.35B), while Biogen Inc trades at $207.48 (market cap $30.13B). The key difference: Boeing Co is far larger — about 6.1× Biogen Inc's market cap, and Boeing Co pays a 0.03% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BA | BIIB | |
|---|---|---|
Market Cap | $184.35B | $30.13B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $216.63 |
52-Week Low | $179.12 | $128.93 |
Enterprise Value | $210.23B | $37.20B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $230.11, down 1.15% on the day, with a bullish technical signal and strong analyst support. The company shows improving fundamentals with 2025 revenue of $89.46 billion and net income of $2.24 billion, marking a return to profitability after three years of losses. Recent news highlights Boeing's strategic divestiture of non-core aviation technology units to Archer Aviation, allowing greater focus on core aerospace operations.
The outlook remains positive with 67% analyst buy ratings and a $280.83 consensus price target representing 22% upside potential. Key risks include execution challenges in production ramp-up, high debt levels, and competitive pressures. Earnings momentum is mixed with a recent Q2 2026 miss but beats in prior quarters, requiring monitoring of Q3 2026 results due soon.
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
